Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Surachat Ngorsuraches & Nabin Poudel. (2021) Incorporating patients’ preferences in the value assessment of disease-modifying therapies for multiple sclerosis: a narrative review. Expert Review of Pharmacoeconomics & Outcomes Research 21:2, pages 183-195.
Read now
Read now
Hamid Reza Nakhaipour, Umakanth Vudumula, Vivek Khurana, Guillaume Sébire, Jean K. Mah, Daniela Pohl, Robyn Schecter & Nicholas Adlard. (2020) Cost-effectiveness of fingolimod versus interferon-β1a for the treatment of pediatric-onset multiple sclerosis in Canada. Journal of Medical Economics 23:12, pages 1525-1533.
Read now
Read now
Mehdi Rezaee, Sadegh Izadi, Khosro Keshavarz, Afshin Borhanihaghighi & Ramin Ravangard. (2019) Fingolimod versus natalizumab in patients with relapsing remitting multiple sclerosis: a cost-effectiveness and cost-utility study in Iran. Journal of Medical Economics 22:4, pages 297-305.
Read now
Read now
Melissa A. Frasco, Tiffany Shih, Devin Incerti, Oliver Diaz Espinosa, Diana K. Vania & Nina Thomas. (2017) Incremental net monetary benefit of ocrelizumab relative to subcutaneous interferon β-1a . Journal of Medical Economics 20:10, pages 1074-1082.
Read now
Read now
Luis Hernandez, Shien Guo, Elizabeth Kinter & Monica Fay. (2016) Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States. Journal of Medical Economics 19:7, pages 684-695.
Read now
Read now
R Brett McQueen, Kavita V Nair, Timothy L Vollmer & Jonathan D Campbell. (2015) Incorporating real-world clinical practice in multiple sclerosis economic evaluations. Expert Review of Pharmacoeconomics & Outcomes Research 15:6, pages 869-872.
Read now
Read now
Ken O’Day, Kellie Meyer, Dana Stafkey-Mailey & Crystal Watson. (2015) Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden. Journal of Medical Economics 18:4, pages 295-302.
Read now
Read now
Radu Tanasescu & Cris S Constantinescu. (2014) Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis. Expert Opinion on Drug Metabolism & Toxicology 10:4, pages 621-630.
Read now
Read now
Articles from other publishers (23)
Staley A. Brod. (2022) The genealogy, methodology, similarities and differences of immune reconstitution therapies for multiple sclerosis and neuromyelitis optica. Autoimmunity Reviews 21:10, pages 103170.
Crossref
Crossref
Mehdi Rezaee, Mohammad Hossein Morowvat, Maryam Poursadeghfard, Armin Radgoudarzi & Khosro Keshavarz. (2022) Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis. BMC Health Services Research 22:1.
Crossref
Crossref
Anggie Wiyani, Lohit Badgujar, Vivek Khurana & Nicholas Adlard. (2021) How have Economic Evaluations in Relapsing Multiple Sclerosis Evolved Over Time? A Systematic Literature Review. Neurology and Therapy 10:2, pages 557-583.
Crossref
Crossref
Staley A. Brod. (2021) Immune reconstitution therapy in NMOSD. Multiple Sclerosis and Related Disorders 52, pages 102971.
Crossref
Crossref
Ingrid E. H. Kremer, Mickael Hiligsmann, Josh Carlson, Marita Zimmermann, Peter J. Jongen, Silvia M. A. A. Evers, Svenja Petersohn, Xavier G. L. V. Pouwels & Nick Bansback. (2020) Exploring the Cost Effectiveness of Shared Decision Making for Choosing between Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis in the Netherlands: A State Transition Model. Medical Decision Making 40:8, pages 1003-1019.
Crossref
Crossref
Anna Mokrova, Susanna Sologova & Victoria Ignatyeva. (2020) Modelling expenses for multiple sclerosis treatment. Farmacevticheskoe delo i tehnologija lekarstv (Pharmacy and Pharmaceutical Technology):3, pages 11-34.
Crossref
Crossref
Staley A. Brod. (2020) In MS: Immunosuppression is passé. Multiple Sclerosis and Related Disorders 40, pages 101967.
Crossref
Crossref
Andrew J Palmer, Ingrid van der Mei, Bruce V Taylor, Philip M Clarke, Steve SimpsonJrJr & Hasnat Ahmad. (2019) Modelling the impact of multiple sclerosis on life expectancy, quality-adjusted life years and total lifetime costs: Evidence from Australia. Multiple Sclerosis Journal 26:4, pages 411-420.
Crossref
Crossref
Damiano Paolicelli, Giuseppe Lucisano, Alessia Manni, Carlo Avolio, Simona Bonavita, Vincenzo Brescia Morra, Marco Capobianco, Eleonora Cocco, Antonella Conte, Giovanna De Luca, Francesca De Robertis, Claudio Gasperini, Maurizia Gatto, Paola Gazzola, Giacomo Lus, Antonio Iaffaldano, Pietro Iaffaldano, Davide Maimone, Giulia Mallucci, Giorgia T. Maniscalco, Girolama A. Marfia, Francesco Patti, Ilaria Pesci, Carlo Pozzilli, Marco Rovaris, Giuseppe Salemi, Marco Salvetti, Daniele Spitaleri, Rocco Totaro, Mauro Zaffaroni, Giancarlo Comi, Maria Pia Amato & Maria Trojano. (2019) Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register. Journal of Neurology 266:12, pages 3098-3107.
Crossref
Crossref
Viktor Chirikov, Ingrid Ma, Namita Joshi, Dipen Patel, Alden Smith, Cindy Giambrone, Noelle Cornelio & Lobat Hashemi. (2019) Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States. Value in Health 22:2, pages 168-176.
Crossref
Crossref
Luis Hernandez, Malinda O’Donnell & Maarten Postma. (2018) Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations. PharmacoEconomics 36:10, pages 1223-1252.
Crossref
Crossref
Diana M. Negoescu, Kostas Bimpikis, Margaret L. Brandeau & Dan A. Iancu. (2018) Dynamic Learning of Patient Response Types: An Application to Treating Chronic Diseases. Management Science 64:8, pages 3469-3488.
Crossref
Crossref
Ramin Ravangard, Mehdi Rezaee, Khosro Keshavarz, Afshin Borhanihaghighi & Sadegh Izadi. (2018) Cost - effectiveness and Cost - utility of CinnoVex versus ReciGen in Patients with Relapsing - Remitting Multiple Sclerosis in Iran. Shiraz E-Medical Journal In Press:In Press.
Crossref
Crossref
Sergio Iannazzo, Ange-Christelle Iliza & Louise Perrault. (2017) Disease-Modifying Therapies for Multiple Sclerosis: A Systematic Literature Review of Cost-Effectiveness Studies. PharmacoEconomics 36:2, pages 189-204.
Crossref
Crossref
Mai F. Alsaqa’aby, Varun Vaidya, Noura Khreis, Thamer Al Khairallah & Ahmed H. Al-jedai. (2017) Cost-effectiveness of oral agents in relapsing-remitting multiple sclerosis compared to interferon-based therapy in Saudi Arabia. Annals of Saudi Medicine 37:6, pages 433-443.
Crossref
Crossref
GJ Melendez-Torres, Peter Auguste, Xavier Armoiry, Hendramoorthy Maheswaran, Rachel Court, Jason Madan, Alan Kan, Stephanie Lin, Carl Counsell, Jacoby Patterson, Jeremy Rodrigues, Olga Ciccarelli, Hannah Fraser & Aileen Clarke. (2017) Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation. Health Technology Assessment 21:52, pages 1-352.
Crossref
Crossref
Aseel Bin Sawad, Enrique Seoane-Vazquez, Rosa Rodriguez-Monguio & Fatema Turkistani. (2017) Cost–effectiveness of different strategies for treatment relapsing-remitting multiple sclerosis. Journal of Comparative Effectiveness Research 6:2, pages 97-108.
Crossref
Crossref
Clayton English & Joseph J. Aloi. (2015) New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis. Clinical Therapeutics 37:4, pages 691-715.
Crossref
Crossref
Xinke Zhang, Joel W. Hay & Xiaoli Niu. (2014) Cost Effectiveness of Fingolimod, Teriflunomide, Dimethyl Fumarate and Intramuscular Interferon-β1a in Relapsing-Remitting Multiple Sclerosis. CNS Drugs 29:1, pages 71-81.
Crossref
Crossref
Mark Sanford. (2014) Fingolimod: A Review of Its Use in Relapsing-Remitting Multiple Sclerosis. Drugs 74:12, pages 1411-1433.
Crossref
Crossref
Shien Guo, Christopher Pelligra, Catherine Saint-Laurent Thibault, Luis Hernandez & Anuraag Kansal. (2014) Cost-Effectiveness Analyses in Multiple Sclerosis: A Review of Modelling Approaches. PharmacoEconomics 32:6, pages 559-572.
Crossref
Crossref
Jonathan D. Campbell, Vahram Ghushchyan, R. Brett McQueen, Sharon Cahoon-Metzger, Terrie Livingston, Timothy Vollmer, John Corboy, Augusto Miravalle, Teri Schreiner, Victoria Porter & Kavita Nair. (2014) Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimates. Multiple Sclerosis and Related Disorders 3:2, pages 227-236.
Crossref
Crossref
Harold L. Atkins & Mark S. Freedman. (2012) Hematopoietic Stem Cell Therapy for Multiple Sclerosis: Top 10 Lessons Learned. Neurotherapeutics 10:1, pages 68-76.
Crossref
Crossref